PolarityTE Announces Matt Kemp as Chief Commercial Officer
An Experienced Commercial Executive with Tenure at Industry Leaders Including Allergan, AbbVie, Zimmer Biomet and Recently with Dendreon's Autologous Cell Therapy
SALT LAKE CITY, Nov. 27, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the appointment of Matt Kemp as Chief Commercial Officer. Mr. Kemp will be integral in leading efforts as SkinTE™ moves toward a full national launch and in bringing other PolarityTE pipeline technologies and core "TE" products to market worldwide.
With nearly 20 years of leadership experience, Mr. Kemp has an extensive record of driving profitable growth in both large and small biotech, medical device and pharmaceutical companies. He most recently served as Chief Commercial Officer at Dendreon Pharmaceuticals, a biotechnology company whose first product is an autologous immunotherapy for the treatment of advanced prostate cancer made from a patient's own immune cells. While at Dendreon, Mr. Kemp helped champion a complete turnaround and the execution of a successful commercial strategy with the novel autologous cellular immunotherapy. Dendreon went from a net negative business to returning three consecutive years of $100+ million in profit during his tenure with the company. Mr. Kemp has also held commercial leadership positions at Zimmer Biomet, Allergan and AbbVie across a variety of technologies, products and markets.
"We at PolarityTE are incredibly excited to have Matt join the rapidly growing PolarityTE family and have him lead the Company's commercial evolution. With his wealth of knowledge, leadership experience and commercialization strategies in advanced product lines, new markets and the development of previously unseen technologies, I believe he is more than equipped to bring this novel and innovative technology platform forward—in a way never seen before," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
"PolarityTE is leading the charge in realizing the full potential of regenerative medicine, and I am delighted to join the leadership team at this critical and exciting time for the Company," said Matt Kemp, Chief Commercial Officer of PolarityTE. He continued, "I look forward to building and leading the commercial team that will take PolarityTE to the next level of growth and deliver on the Company's mission to bring innovative therapies to market that will improve patients' lives."
About Matt Kemp
A highly experienced senior healthcare executive, Mr. Kemp has nearly 20 years of leadership experience across multiple therapeutic areas in the medical device, pharmaceutical and biotech industries. He has a proven track record of leading successful businesses in complex, competitive and turn-around environments. Prior to joining PolarityTE, Mr. Kemp served as Chief Commercial Officer at Dendreon Pharmaceuticals LLC, a pioneer in personalized medicine. Prior to Dendreon, Mr. Kemp held commercial leadership positions at Zimmer Biomet, Allergan and AbbVie. Mr. Kemp also served six years in the Air Force, rising to the rank of Captain. Mr. Kemp earned his B.S. degree from Purdue University.
About PolarityTE®
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
About SkinTE™
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
CONTACTS
Investors:
Rich Haerle
VP, Investor Relations
PolarityTE, Inc.
ir@PolarityTE.com
(385) 831-5284
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 535-7743
Media:
Jenna Mathis
PolarityTE, Inc.
JennaMathis@polarityTE.com
(610) 751-3985
View original content to download multimedia:http://www.prnewswire.com/news-releases/polarityte-announces-matt-kemp-as-chief-commercial-officer-300755630.html
SOURCE PolarityTE, Inc.
Company Codes: NASDAQ-NMS:PTE